Biophytis SA is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of age-related diseases. The company's lead product candidate, BI-101, is a first-in-class, oral, small molecule that activates the gut-brain axis to improve muscle function and mobility in people with amyotrophic lateral sclerosis (ALS). BI-101 is currently in Phase 2 clinical trials.
Biophytis also has a second product candidate, BI-501, which is a first-in-class, oral, small molecule that activates the AMPK pathway to improve muscle function and mobility in people with sarcopenia, a muscle wasting condition that is common in older adults. BI-501 is currently in Phase 1 clinical trials.
In addition to its two lead product candidates, Biophytis is also developing a pipeline of other products for the treatment of age-related diseases. These include:
- BI-601, a first-in-class, oral, small molecule that activates the SIRT1 pathway to improve cognitive function in people with Alzheimer's disease.
- BI-701, a first-in-class, oral, small molecule that activates the FOXO pathway to improve cardiovascular function in people with heart failure.
- BI-801, a first-in-class, oral, small molecule that activates the Nrf2 pathway to improve kidney function in people with chronic kidney disease.
Biophytis is headquartered in France and has a research and development center in Switzerland. The company is listed on the Nasdaq stock exchange under the ticker symbol "BPTS".
Here is a more detailed description of Biophytis' lead product candidates:
- BI-101 is a first-in-class, oral, small molecule that activates the gut-brain axis to improve muscle function and mobility in people with ALS. The gut-brain axis is a communication pathway between the gut and the brain. It is thought that this pathway plays a role in the development of ALS. BI-101 works by activating a receptor in the gut called GPR43. This receptor is thought to be involved in the communication between the gut and the brain. When BI-101 activates GPR43, it sends a signal to the brain that tells the brain to improve muscle function.
BI-101 is currently in Phase 2 clinical trials. The first Phase 2 trial in ALS patients is expected to be completed in 2023. If the trial is successful, Biophytis plans to conduct a second Phase 2 trial in ALS patients.
- BI-501 is a first-in-class, oral, small molecule that activates the AMPK pathway to improve muscle function and mobility in people with sarcopenia. Sarcopenia is a muscle wasting condition that is common in older adults. It is characterized by a loss of muscle mass and strength. BI-501 works by activating a protein called AMPK. AMPK is a master regulator of metabolism. When BI-501 activates AMPK, it tells the body to increase muscle protein synthesis and decrease muscle protein breakdown. This leads to an increase in muscle mass and strength.
BI-501 is currently in Phase 1 clinical trials. The first Phase 1 trial in healthy volunteers is expected to be completed in 2023. If the trial is successful, Biophytis plans to conduct a Phase 2 trial in sarcopenia patients.
Biophytis is a clinical-stage biopharmaceutical company with a promising pipeline of products for the treatment of age-related diseases. The company's lead product candidates, BI-101 and BI-501, have the potential to improve the lives of millions of people around the world.
